Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table A20–1 Incidence Rate for Respiratory Syncytial Virus Infection

Age Groups

Population

Incidence Rates (per 100,000)

Cases

<1

3,963,000

25,233.41

1,000,000

1–4

16,219,000

12331.22

2,000,000

5–14

38,056,000

822.19

312,892

15–24

36,263,000

822.19

298,150

25–34

41,670,000

822.19

342,606

35–44

42,149,000

822.19

346,545

45–54

30,224,000

822.19

248,498

55–64

21,241,000

822.19

174,641

65–74

18,964,000

822.19

155,920

75–84

11,088,000

822.19

91,164

85+

3,598,000

822.19

29,582

Total

263,435,000

 

COST INCURRED BY DISEASE

Table A20–3 summarizes the health care costs incurred by RSV infections. For the purposes of the calculations in this report, it was assumed that treatment of pharyngitis and otitis media are associated with physician visit, diagnostic, and medication (over-the-counter, symptomatic treatment). It was estimated that 100% of children 4 years of age and under incur such treatment but that approximately 50% of people 5 years of age and older seek such medical treatment.

It was assumed that the majority of cases of lower respiratory infections are treated as an outpatient and involve costs similar to that for pharyngitis, but with the addition of an extra physician visit. For the small number of cases of lower respiratory disease which is treated as an inpatient, hospitalization costs are added to the costs similar to that incurred as outpatient treatment. It was assumed that while 100% of children 4 years of age and under receive treatment for lower respiratory infections, only 50% of people 5 years of age or older who are not hospitalized for lower respiratory RSV infections seek medical treatment.

VACCINE DEVELOPMENT

The committee assumed that it will take 7 years until licensure of a RSV vaccine and that $360 million needs to be invested. It was assumed that the same vaccine would be used in infants and in adolescent girls. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement